BioNTech AG, a German company with messenger RNA technology suitable for human therapeutics, has signed a multi-year licensing deal with Sanofi SA to discover and develop up to five cancer immunotherapies. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
